According to the Food and Drug Administration (FDA), about 70% of adults in the U.S. are obese or overweight. That tells you all you need to know about why weight-loss drugs from Eli Lilly & Company (LLY) and Novo Nordisk (NVO) have become such hot sellers that neither company can keep up with demand.
This new class of weight loss drugs — known as GLP-1 — need to be taken consistently for lasting results. That’s why J.P. Morgan thinks sales of these drugs could exceed $100 billion by 2030!
